↓ Skip to main content

Cochrane Database of Systematic Reviews

Nicotine for Alzheimer's disease

Overview of attention for article published in Cochrane database of systematic reviews, April 2001
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

1 news outlet
1 policy source
15 tweeters
2 patents


13 Dimensions

Readers on

132 Mendeley
Nicotine for Alzheimer's disease
Published in
Cochrane database of systematic reviews, April 2001
DOI 10.1002/14651858.cd001749
Pubmed ID

Jess López-Arrieta, Francisco José FJS Sanz


Nicotine is a cholinergic agonist that acts, not only post-synaptically, but also releases pre-synaptic acetylcholine, and in animal models has been shown to reverse spatial memory decline in rats with lesion in the medial septal nucleus and to show recovery on memory in aged monkeys. Nicotine also has effects on other transmitters like serotonin (5HT), dopamine, or GABA. On the other hand, because nicotine has serious adverse effects, especially concerning cardiovascular risks in elderly people, and also on sleep and behavior, there are several important reasons to conduct a systematic review to assess the clinical efficacy and safety of nicotine in patients with AD. The aim of this review is to determine whether there is evidence of beneficial effect, and to assess its safety profile, when nicotine is used for Alzheimer's disease. The Cochrane Controlled Trials Register (Issue 2, 99) was searched using the terms nicotin* and alzheimer*. Three references to trials were deemed suitable for inclusion but are awaiting consideration while the investigators are contacted. All unconfounded, double-blind, randomized trials in which treatment with nicotine patches or administration of nicotine intravenously was administered for more than a day and compared to placebo in people with Alzheimer's disease. As no trials were suitable for inclusion, no data have been extracted or pooled in a meta-analysis. One trial is awaiting consideration, and if included in an update of this review, any available data will be incorporated. The poor quality of the trials did not allow any synthesis of results across studies. However, the data available in trials considered are compatible with nicotine producing harm, no change or improvement. This review is not able to provide reliable evidence that nicotine is a useful treatment for Alzheimer's disease.

Twitter Demographics

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Spain 1 <1%
Iceland 1 <1%
Unknown 129 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 22 17%
Student > Master 13 10%
Student > Postgraduate 11 8%
Student > Ph. D. Student 10 8%
Other 8 6%
Other 26 20%
Unknown 42 32%
Readers by discipline Count As %
Medicine and Dentistry 28 21%
Psychology 11 8%
Nursing and Health Professions 9 7%
Pharmacology, Toxicology and Pharmaceutical Science 8 6%
Neuroscience 5 4%
Other 23 17%
Unknown 48 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2023.
All research outputs
of 24,395,432 outputs
Outputs from Cochrane database of systematic reviews
of 12,904 outputs
Outputs of similar age
of 41,623 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 28 outputs
Altmetric has tracked 24,395,432 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,904 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 41,623 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.